Kraig Biocraft Laboratories produced over 1.3 metric tons of recombinant spider silk cocoons in a single calendar month — five times the company’s previous record. The announcement, made on 6 April 2026, is not primarily a chemistry story. It is a procurement story: 1.3 MT/month puts Kraig Biocraft’s recombinant spider silk within the volume range at which defence contractors, medical device manufacturers, and aerospace suppliers can begin material qualification testing — the gateway to commercial supply chain integration. That shift, not the material’s mechanical properties, is what changed on 6 April.

The milestone matters because recombinant spider silk has been a lab success story for years, and this monthly volume is the first clear sign it can reach factory scale.
Why Recombinant Spider Silk Couldn’t Scale Before
Spider silk’s mechanical properties have been documented for decades. Dragline silk — the structural anchor fibre — has a tensile strength of approximately 1.3 GPa at a density of roughly 1.3 g/cm³. Steel at equivalent tensile strength weighs approximately six times more per unit volume. Kevlar 49 has a tensile strength of approximately 3.6 GPa (per DuPont’s published material datasheet) — meaningfully higher than spider silk’s ~1.3 GPa on an absolute basis. However, spider silk’s advantage lies in specific tensile strength — strength relative to density.
At roughly one-sixth the density of Kevlar, recombinant spider silk demonstrates a strength-to-weight ratio that exceeds Kevlar’s, which is the property that matters for body armour, where minimising carried weight is a design constraint. Spider silk’s energy absorption before fracture — its toughness modulus — is also substantially higher than Kevlar’s, which matters more in ballistic and impact applications than peak tensile strength alone.
The production problem was never the chemistry. Spiders are territorial, cannibalistic, and cannot be farmed at density. Every previous attempt at industrial-scale spider silk — Nexia Biotechnologies’ spider-goat transgenic programme in the early 2000s, Bolt Threads’ yeast-fermentation route, Spiber’s microbial expression approach — either hit hard yield ceilings or retreated toward cosmetics and fashion, where premium pricing tolerates low volumes.
A similar lab-to-factory gap defines the solid-state battery production race, where pilot results only matter once output is steady. Recombinant spider silk faces the same test: consistent batches matter more than a single record month.
Kraig Biocraft’s route to recombinant spider silk is different in a structurally important way. The company engineers Bombyx mori — the conventional mulberry silkworm — to express dragline spider silk proteins (MaSp1 and MaSp2) alongside the silkworm’s native fibre. The Bombyx mori silkworm serves as a biological factory: its natural silk-producing apparatus can be reprogrammed to express foreign proteins, making it a potentially generalisable platform for recombinant structural proteins beyond spider silk. Bombyx mori has been farmed industrially for millennia. The entire infrastructure for rearing silkworms at scale — mulberry cultivation, rearing sheds, cocoon reeling — is already built and concentrated in Southeast Asia. By inserting spider silk gene cassettes into an animal already embedded in a global supply chain, Kraig Biocraft inherits that infrastructure rather than building parallel manufacturing from scratch.
What 1.3 Metric Tons Per Month Actually Unlocks
The jump to 1.3 MT/month matters because material qualification in defence and medical contexts has minimum volume thresholds that are not negotiable. A body-armour panel requires hundreds of kilograms of fibre to run ballistic testing across multiple configurations. A medical suture qualification programme requires consistent, traceable batches over multiple production runs. Below a few hundred kilograms per month — a threshold based on standard materials qualification requirements, which typically involve multi-kilogram samples for ballistic testing, tensile characterisation, and certification testing across multiple batches — a buyer’s engineering team lacks sufficient material to begin qualification. At 1.3 MT/month, Kraig Biocraft has crossed that practical threshold.
Materials engineering is also being accelerated by software, as seen in AI-driven materials discovery work on stable crystal structures. Procurement teams evaluating recombinant spider silk will look for repeatable tensile performance across production runs, and qualification timelines depend on that repeatability.
It is not yet the volume required to displace Kevlar in an active procurement programme — that would require years of supply chain development — but it is sufficient to initiate the conversations that lead there. Defence contractors can request samples, run independent testing, and begin internal feasibility assessments. Medical device manufacturers can engage with regulatory affairs teams on material qualification pathways. Aerospace composites engineers can begin evaluating fibre-matrix compatibility. None of those conversations were commercially rational when monthly output was in the hundreds of kilograms.
The company’s stated target of 10 metric tons per month would, if reached, put recombinant spider silk would, if reached, put the material within the range required for initial volume supply agreements with a small number of industrial customers. The current record is roughly 13% of that ceiling.
Application Readiness by Sector
Defence and ballistics. Spider silk’s combination of high specific strength and toughness modulus makes it an engineering candidate for soft body armour inserts and blast-mitigation panels. Kevlar and ultra-high-molecular-weight polyethylene (UHMWPE/Dyneema) currently dominate this market. The case for spider silk is not that it replaces either at equivalent cost — it almost certainly cannot at current production economics — but that it opens design configurations unavailable with stiffer synthetics. Flexible, high-toughness panels are a long-standing priority for infantry applications. Any supplier conversation here will require independently certified ballistic performance data, which Kraig Biocraft has not yet publicly disclosed at commercial scale.
Medical devices and sutures. In clinical contexts, recombinant spider silk is biocompatible and biodegradable, properties that make it a candidate for absorbable sutures and scaffolding in regenerative medicine applications. Existing absorbable suture materials — polyglycolic acid, polylactic acid, gut — have well-characterised degradation profiles; spider silk’s profile in the specific transgenic formulation used by Kraig Biocraft would require clinical-grade characterisation. This is a longer regulatory path than defence, but the addressable market — the global surgical sutures market was valued at approximately $4.5 billion in 2023 per Grand View Research, with compound annual growth driven by minimally invasive surgical adoption — justifies the effort.
Aerospace composites. Carbon fibre reinforced polymer (CFRP) is the benchmark in aerospace structures. Spider silk’s relevance here is not in load-bearing primary structure — carbon fibre’s tensile modulus substantially exceeds spider silk’s — but in secondary applications where the property profile is more compelling: flexible interior cabin panels (where impact toughness matters more than stiffness), vibration-isolating mounts in avionics enclosures, and lightweight structural tethers. Spider silk-based composites would also be biodegradable, unlike carbon fibre, reducing end-of-life disposal regulation complexity. This is the most distant commercial application of the three.
What to Watch
On 13 April 2026, Kraig Biocraft confirmed leadership travel to Southeast Asia to advance expansion of production facilities. Neither press release names the specific country or partner. The identity of that facility — and whether it is a new build, an expansion of existing silkworm farming capacity, or a joint venture with a regional textile manufacturer — will determine whether the path to 10 MT/month is a capital question or an operations question.
Two open questions define the near-term outlook. First, cost per kilogram at scale: Kraig Biocraft has not disclosed pricing, and without that figure it is not possible to assess whether defence or medical procurement teams can build a commercially rational case. Second, the competing approaches: Bolt Threads and Spiber both ran into yield-consistency problems when scaling microbial fermentation. Whether the silkworm-expression route encounters analogous consistency challenges at higher volumes — fibre diameter variation, protein ratio consistency across rearing batches — will determine whether 1.3 MT/month is a plateau or a waypoint.
The silkworm-expression system is also a template. If Kraig Biocraft’s approach proves that inserting protein expression into an established agricultural organism with existing supply chain infrastructure is a viable path to industrial-scale recombinant protein fibre, the model is transferable. Researchers working on recombinant collagen, elastin, and other structural proteins will be watching the production data closely.
This article was produced with AI assistance and reviewed by the editorial team.
Expect more recombinant spider silk announcements to focus on yield and consistency rather than new property claims. Each new volume record moves the material closer to commercial supply contracts.